Cargando…
HPV Testing With 16, 18, and 45 Genotyping Stratifies Cancer Risk for Women With Normal Cytology: Data From the Baseline Phase of the Onclarity Trial
OBJECTIVES: To determine the BD Onclarity human papillomavirus (HPV) assay performance and risk values for cervical intraepithelial neoplasia grade 2 (CIN2) or higher and cervical intraepithelial neoplasia grade 3 (CIN3) or higher during Papanicolaou/HPV cotesting in a negative for intraepithelial l...
Autores principales: | Stoler, Mark H, Wright, Thomas C, Parvu, Valentin, Yanson, Karen, Eckert, Karen, Kodsi, Salma, Cooper, Charles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396747/ https://www.ncbi.nlm.nih.gov/pubmed/30649177 http://dx.doi.org/10.1093/ajcp/aqy169 |
Ejemplares similares
-
Detection of Cervical Neoplasia by Human Papillomavirus Testing in an Atypical Squamous Cells-Undetermined Significance Population: Results of the Becton Dickinson Onclarity Trial
por: Wright, Thomas C, et al.
Publicado: (2019) -
Bayesian analysis of baseline risk of CIN2 and ≥CIN3 by HPV genotype in a European referral cohort
por: Bonde, Jesper, et al.
Publicado: (2019) -
Analytical and Clinical Sample Performance Characteristics of the Onclarity Assay for the Detection of Human Papillomavirus
por: Young, Stephen, et al.
Publicado: (2020) -
Comparison of Seegene Anyplex II HPV28 assay with BD Onclarity HPV assay for human papillomavirus genotyping
por: Kim, Moonsik, et al.
Publicado: (2022) -
Detection of high-risk HPV in FFPE specimens of various tumours using the BD Onclarity™ HPV Assay
por: van der Geize, Robert, et al.
Publicado: (2022)